Excimer laser versus clobetason propionaat in prurigo form of atopic dermatitis

INTERVENTION: Trade Name: Dermovate Product Name: Dermovate Product Code: RVG06933 Pharmaceutical Form: Ointment INN or Proposed INN: CLOBETASOL PROPIONATE CAS Number: 25122467 Concentration unit: % (W/W) percent weight/weight Concentration type: equal CONDITION: the excimer laser appears to be a promising treatment for localized atopic dermatitis. Therefore we designed a randomized trial to investigate the efficacy of this excimer laser versus topical clobetasol propionaat in patients with the prurigo form of atopic dermatitis. PRIMARY OUTCOME: Main Objective: to investigate the efficacy of XeCl excimer laser therapy versus topical corticosteroid in a side‐to‐side comparison in patients with the prurigo form of AD. Primary end point(s): Efficacy of the excimer laser in prurigo form of AD. Secondary Objective: to assess the duration of remissions achieved with excimer laser and to evaluate the patient’s and investigator’s satisfaction/preferences regarding both treatments. INCLUSION CRITERIA: Diagnosis of the prurigo form of AD is based on : o Hanifin and Rajka Diagnostic Criteria(10) o Presence of allergen specific IgE(9) o Prurigo nodules Therapy resistant prurigo lesions, > 6 months, without spontaneous remission At least 4 symmetrical prurigo lesions/nodules, on lower or upper extremities Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range